Xilio Therapeutics (XLO) Enterprise Value (2020 - 2026)
Xilio Therapeutics (XLO) posted Enterprise Value of -$150.3 million for Q1 2026, down 9.28% sequentially from -$137.5 million in Q4 2025, and down 68.74% YoY from -$480.8 million in Q1 2025.
Xilio Therapeutics (XLO) Enterprise Value (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$150.3 million in Q1 2026.
- Quarterly Enterprise Value fell 68.74% year-over-year to -$150.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$150.3 million (down 68.74% YoY) and the FY2025 annual result came in at -$137.5 million, down 148.74% from the prior year.
- Enterprise Value eased to -$150.3 million in Q1 2026 per XLO's latest filing, from -$137.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$34.0 million in Q1 2024 and troughed at -$177.0 million in Q1 2022.
- A 5-year average of -$99.8 million and a median of -$93.3 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 63.57% in 2024, then plunged 162.13% in 2025.
- Over 5 years, Enterprise Value stood at -$120.4 million in 2022, then jumped by 62.87% to -$44.7 million in 2023, then retreated by 23.68% to -$55.3 million in 2024, then slumped by 148.74% to -$137.5 million in 2025, then dropped by 9.28% to -$150.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$150.3 million, -$137.5 million, and -$103.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | -136.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -136.04 Mn |
| Mar 31, 2026 | -150.30 Mn |
| Dec 31, 2025 | -137.53 Mn |
| Sep 30, 2025 | -103.76 Mn |
| Jun 30, 2025 | -121.55 Mn |
| Mar 31, 2025 | -89.07 Mn |
| Dec 31, 2024 | -55.29 Mn |
| Sep 30, 2024 | -61.26 Mn |
| Jun 30, 2024 | -74.95 Mn |
| Mar 31, 2024 | -33.98 Mn |
| Dec 31, 2023 | -44.70 Mn |
| Sep 30, 2023 | -59.77 Mn |
| Jun 30, 2023 | -75.38 Mn |
| Mar 31, 2023 | -93.27 Mn |
| Dec 31, 2022 | -120.39 Mn |
| Sep 30, 2022 | -139.14 Mn |
| Jun 30, 2022 | -159.41 Mn |
| Mar 31, 2022 | -176.96 Mn |
| Dec 31, 2021 | -198.05 Mn |
| Sep 30, 2021 | -99.77 Mn |